Sumitomo Pharma Co. Ltd. (DNPUF)
Sumitomo Pharma Statistics
Share Statistics
Sumitomo Pharma has 397.29M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 397.29M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 154.89M |
| Failed to Deliver (FTD) Shares | - |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -0.5 and the forward PE ratio is null. Sumitomo Pharma's PEG ratio is 0.
| PE Ratio | -0.5 |
| Forward PE | n/a |
| PS Ratio | 0.5 |
| Forward PS | n/a |
| PB Ratio | 1 |
| P/FCF Ratio | -0.61 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Sumitomo Pharma.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.52, with a Debt / Equity ratio of 2.74.
| Current Ratio | 0.52 |
| Quick Ratio | 0.3 |
| Debt / Equity | 2.74 |
| Debt / EBITDA | -1.35 |
| Debt / FCF | -1.66 |
| Interest Coverage | -82.97 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $63.16M |
| Profits Per Employee | $-63.25M |
| Employee Count | 4,980 |
| Asset Turnover | 0.35 |
| Inventory Turnover | 1.1 |
Taxes
| Income Tax | -8.19B |
| Effective Tax Rate | 2.53% |
Stock Price Statistics
The stock price has increased by 114.81% in the last 52 weeks. The beta is 0.54, so Sumitomo Pharma's price volatility has been higher than the market average.
| Beta | 0.54 |
| 52-Week Price Change | 114.81% |
| 50-Day Moving Average | 4.55 |
| 200-Day Moving Average | 4.13 |
| Relative Strength Index (RSI) | 87.81 |
| Average Volume (20 Days) | 81 |
Income Statement
In the last 12 months, Sumitomo Pharma had revenue of 314.56B and earned -314.97B in profits. Earnings per share was -792.79.
| Revenue | 314.56B |
| Gross Profit | 187.98B |
| Operating Income | -354.86B |
| Net Income | -314.97B |
| EBITDA | -317.37B |
| EBIT | -318.84B |
| Earnings Per Share (EPS) | -792.79 |
Balance Sheet
The company has 29.05B in cash and 427.86B in debt, giving a net cash position of -398.82B.
| Cash & Cash Equivalents | 29.05B |
| Total Debt | 427.86B |
| Net Cash | -398.82B |
| Retained Earnings | -22.66B |
| Total Assets | 868.93B |
| Working Capital | -172.53B |
Cash Flow
In the last 12 months, operating cash flow was -241.89B and capital expenditures -15.73B, giving a free cash flow of -257.62B.
| Operating Cash Flow | -241.89B |
| Capital Expenditures | -15.73B |
| Free Cash Flow | -257.62B |
| FCF Per Share | -648.45 |
Margins
Gross margin is 59.76%, with operating and profit margins of -112.81% and -100.13%.
| Gross Margin | 59.76% |
| Operating Margin | -112.81% |
| Pretax Margin | -102.72% |
| Profit Margin | -100.13% |
| EBITDA Margin | -100.89% |
| EBIT Margin | -112.81% |
| FCF Margin | -81.9% |
Dividends & Yields
DNPUF pays an annual dividend of $0.26, which amounts to a dividend yield of 2.34%.
| Dividend Per Share | $0.26 |
| Dividend Yield | 2.34% |
| Dividend Growth (YoY) | -53.76% |
| Payout Ratio | -8.56% |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for DNPUF.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | -0.97 |
| Piotroski F-Score | 4 |